文献速递骨软组织肉瘤与黑色素瘤

T-VEC联合帕博利珠单抗治疗局部晚期或转移性肉瘤的2期临床试验

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.
PubMed 文献 · JAMA Oncol · 2020-01-01

这项开放标签、单中心2期试验纳入20例至少一线系统治疗失败的局部晚期或转移性肉瘤患者,接受瘤内T-VEC联合静脉帕博利珠单抗治疗。24周最佳客观缓解率(RECIST 1.1)为30%(95%CI 12%-54%,n=6),总体ORR为35%(95%CI 15%-59%,n=7),3级治疗相关不良事件发生率为20%(4例),无4级不良事件或治疗相关死亡。

要点

  • T-VEC联合帕博利珠单抗在晚期肉瘤中24周最佳ORR达30%,总体ORR达35%。
  • 3级治疗相关不良事件发生率为20%,无4级事件或治疗相关死亡。
  • 该联合方案在多种肉瘤组织学亚型中显示抗肿瘤活性,安全性可控。

核心结论

  • T-VEC联合帕博利珠单抗在晚期肉瘤中显示抗肿瘤活性,安全性可控,达到预设主要终点。

研究设计与样本

  • 开放标签、单中心2期干预性试验,2017年3月16日至12月4日入组20例至少一线系统治疗失败的局部晚期或转移性肉瘤患者,中位治疗时长16周(范围7-67周),分析数据截至2018年12月14日。

主要发现

  • 24周最佳ORR(RECIST 1.1)为30%(95%CI 12%-54%,n=6),总体ORR为35%(95%CI 15%-59%,n=7)。
  • 3级治疗相关不良事件发生率为20%(4例),无4级治疗相关不良事件或治疗相关死亡。

临床怎么用

  • 对于至少一线系统治疗失败的局部晚期或转移性肉瘤患者,可考虑T-VEC联合帕博利珠单抗作为可选方案,尤其适用于多种组织学亚型。

局限性

  • 单中心、开放标签、样本量小(20例),缺乏随机对照,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. OBJECTIVE: To examine whether T-VEC in combination with pembrolizumab is associated with increased tumor-infiltrating lymphocyte infiltration and programmed death-ligand 1 expression and thus with increased antitumor activity in patients with locally advanced or metastatic sarcoma. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-institution phase 2 interventional trial of T-VEC plus pembrolizumab enrolled 20 patients with locally advanced or metastatic sarcoma between March 16 and December 4, 2017, for whom at least 1 standard systemic therapy had failed. The median duration of therapy was 16 weeks (range, 7-67 weeks). Reported analyses include data through December 14, 2018. INTERVENTION: Patients received pembrolizumab (200-mg flat dose) intravenously and T-VEC (first dose, ≤4 mL × 106 plaque-forming units [PFU]/mL; second and subsequent doses, ≤4 mL × 108 PFU/mL) injected into palpable tumor site(s) on day 1 of each 21-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate (ORR; complete response and partial response) at 24 weeks determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, criteria. Secondary end points included best ORR by immune-related RECIST criteria, progression-free survival rate at 24 weeks, overall survival, and safety. RESULTS: All 20 patients (12 women [60%]; median age, 63.5 years [range, 24-90 years]) were evaluable for response. The study met its primary end point of evaluating the best ORR at 24 weeks determined by RECIST, version 1.1, criteria; the best ORR was 30% (95% CI, 12%-54%; n = 6). The ORR overall was 35% (95% CI, 15%-59%; n = 7). The incidence of grade 3 treatment-related adverse events was low (4 patients [20%]). There were no grade 4 treatment-related adverse events or treatment-related deaths. CONCLUSIONS AND RELEVANCE: In this phase 2 clinical trial, treatment with T-VEC plus pembrolizumab was associated with antitumor activity in advanced sarcoma across a range of sarcoma histologic subtypes, with a manageable safety profile. This combination therapy met its predefined primary study end point; further evaluation of T-VEC in combination with pembrolizumab for patients with select sarcoma subtypes is planned. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03069378.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Kelly CM, Antonescu CR, Bowler T, et al. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA Oncol. 2020. PMID: 31971541. doi:10.1001/jamaoncol.2019.6152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。